Details of the Drug Reposition

General Information of This Drug (ID: DMP8HW1)

• Drug Name: LY2157299 (DMP8HW1)
• Synonyms: Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

2 Phase 2/3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-small-cell lung cancer	DIS5Y6R9	2C25.Y	Phase 2/3	[1]
Arteriosclerosis	DISK5QGC	BD40	Phase 2/3	[2]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hepatocellular carcinoma	DIS0J828	2C12.02	Phase 2	[1]

2 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Glioma	DIS5RPEH	2A00.0	Phase 1/2	[3]
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 1/2	[1]

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pancreatic cancer	DISJC981	2C10	Phase 1	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7797).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)